On November 30, 2021 Hamlet Pharma reported that it is proceeding with the development of BAMLET for pharmaceutical use (Press release, HAMLET Pharma, NOV 30, 2021, View Source;utm_medium=rss&utm_campaign=hamlet-pharma-has-signed-a-collaboration-agreement-with-galenica [SID1234596241]). A necessary first step is to establish technology for large-scale production of BAMLET. A new production method has been developed and patented and will be used as a basis for scaling up the production process together with Galenica AB.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Galenica AB is a contract research organisation (CRO) providing services in the field of pharmaceutical technology. The company has broad skills and experience in formulation, production and quality control of pharmaceuticals.

The parties have agreed to a development plan, including production technology transfer, testing of biological activity of the product and development of suitable formulations.

‘’BAMLET is a fascinating molecule with potent effects on tumor cells and in animal models of cancer’’ says Catharina Svanborg, Chairman, Hamlet Pharma.

‘’We are pleased to move forward with our second drug candidate and extend the Hamlet Pharma portfolio’’, says Mats Persson, CEO, Hamlet Pharma.

This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-11-2021 08:50 CET.